Life Magnetics

Isolation and transport of RNA for medical testing, research, and drug delivery is historically very difficult.  Compared to DNA's half life of 531 years, RNA has a half life of just 28 minutes.

COVID-19 has shown that this esoteric laboratory challenge is a huge business opportunity.  Early on, we saw constant shortages of viral transport media needed to ship samples for diagnostic testing.  More recently, the RNA-based vaccines are often in the news because of the challenges associated with keeping them refrigerated.

RNA is the future of medicine. The mRNA COVID-19 vaccines are just the beginning
RNA sequencing will revolutionize diagnostic testing giving data sets 20x larger than DNA sequencing
Our transport solution is a quantum mechanical mechanism that's novel and vetted by top scientist
Manufacturing capacity for $2M a year in sales built out and ready to go
Licensing deals and larger supply agreements in discussion
Development supported with over $600k in grants from federal agencies

$200,022

• Advertising and sales support to generate revenue at university labs, which was the majority of our revenue pre-COVID (e.g. Google ad words, how-to video, sales staff) - 31.5%
• Application of the product to manufacturing RNA drugs such as the COVID-19 vaccine to address specific manufacturing issues. (Separating double stranded RNA from single stranded RNA) - 31%
• Additional sales and technical support for labs using or seeking to use our product in COVID-19 testing which is currently the majority of revenue - 30%
• Wefunder Fee - 7.5%

$600,015

• Seminars at universities around the US to develop collaborations for RNA based at-home testing. - 30%
• Add genomic testing equipment to support application development. - 62.5%
• WeFunder fee - 7.5%

$1,000,008

• Build out facility for at-home testing in collaboration with CMU to deploy a test which will demonstrate our unique capabilities. Opportunities are being evaluated but likely options are a urine-based at-home prostate cancer test or a saliva-based at-home COVID-19 test - 92.5%
• WeFunder fee - 7.5%

Kevin Hagedorn
President
Performed physics simulations establishing a theoretical basis for the product, developed a manufacturing process, and was awarded two grants from the National Science Foundation to develop a commercial prototype for the product.

Rishabh Kala Board member, CTO
Performed research on aging at the University of Michigan. Transformed the raw material and idea into a working product with excellent reviews from the local universities. Discovered a new COVID-19 variant and set up a COVID-19 testing lab.

Price per Share: $51.00